Table 2. Summary of Recommendations for Antimicrobial
Prophylaxis
Type of
prophylaxis Population Recommendations Timing of prophylaxis
Antiviral
(cont'd)
Patients at
substantial risk
of reactivation of
HBV infection
Treatment with a
nucleoside reverse
transcriptase inhibitor
(e.g. entecavir,
tenofovir)
See Updated ASCO
HBV Provisional Clinical
Opinion (Hwang et al.
J Clin Oncol. 33:2212–
2220, 2015)
Any individuals
treated with
chemotherapy
for malignancy
and family and
household contacts
Administration
of inactivated
influenza vaccine is
recommended for
household contacts and
healthcare providers.
• Optimal timing of
vaccination for patients
being treated for cancer
is not established, but
serologic responses
may be best between
chemotherapy cycles
(>7 days after the last
treatment) or >2 weeks
before chemotherapy
starts.
• Patients with cancer
and their household
contacts should be
immunized annually.
• Influenza vaccination
response appears to
be best in HSCT
recipients if vaccinated
>6 months after
transplantation.
Immunosuppressed
adult oncolog y
patients
e Expert Panel
also supports
other vaccination
recommendations for
immunosuppressed
adult oncolog y
patients that are
contained within the
IDSA guideline for
vaccination of the
immunosuppressed
host.
Not applicable
Rubin LG, Levin MJ, Ljungman P, et al: 2013 IDSA clinical practice guideline for vaccination of the
immunocompromised host. Clin Infect Dis 58:e44-100, 2014.
(cont'd)
